The Manufacturers Life Insurance Company Acquires 3,706 Shares of Savara Inc (NASDAQ:SVRA)

The Manufacturers Life Insurance Company boosted its holdings in shares of Savara Inc (NASDAQ:SVRA) by 9.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 44,956 shares of the company’s stock after purchasing an additional 3,706 shares during the period. The Manufacturers Life Insurance Company’s holdings in Savara were worth $191,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Choreo LLC acquired a new stake in Savara in the 2nd quarter valued at $59,000. DRW Securities LLC bought a new position in shares of Savara during the second quarter valued at $62,000. Principal Financial Group Inc. boosted its stake in shares of Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after purchasing an additional 6,973 shares in the last quarter. Profund Advisors LLC bought a new stake in shares of Savara in the 2nd quarter worth about $105,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Savara by 95.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 31,658 shares of the company’s stock worth $134,000 after purchasing an additional 15,423 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction on Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. The trade was a 3.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Joseph S. Mccracken bought 20,000 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was bought at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the purchase, the director now directly owns 210,837 shares of the company’s stock, valued at approximately $621,969.15. This trade represents a 10.48 % increase in their position. The disclosure for this purchase can be found here. 5.13% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research note on Tuesday, October 1st. Evercore ISI restated an “in-line” rating and set a $5.00 price target (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. Finally, HC Wainwright cut their price objective on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Stock Up 1.6 %

NASDAQ SVRA opened at $3.26 on Tuesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara Inc has a 52 week low of $2.82 and a 52 week high of $5.70. The stock has a market capitalization of $559.48 million, a P/E ratio of -7.58 and a beta of 0.92. The stock has a fifty day moving average of $3.51 and a 200-day moving average of $4.01.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). On average, equities research analysts forecast that Savara Inc will post -0.45 EPS for the current year.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.